

## Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website: www.sunpharma.com  
CIN: L24230GJ1993PLC019050



**FOR IMMEDIATE RELEASE**

## **Sun Pharma to introduce complete range of Brivaracetam at an affordable price for epilepsy treatment in India**

- Brivaracetam is an anti-epileptic drug (AEDs) with fast onset of action and promising efficacy<sup>1</sup>
- Sun Pharma's brand, **Brevipil** is the branded generic version of the innovator product, BRIVIACT® (Brivaracetam)
- Company to introduce Brevipil tablet 25 mg/50 mg/75 mg/100 mg, oral solution (10 mg/ml) and injectable (10 mg/ml)

**Mumbai, India, February 23, 2021** – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that the company will introduce the complete range of Brivaracetam dosage forms at an affordable price for epilepsy treatment in India. Sun Pharma's brand, **Brevipil** (Brivaracetam) tablet 25 mg/50 mg/75 mg/100 mg was launched in the market on Day-1 post patent expiry of innovator product (February 21, 2021). Brevipil oral solution (10 mg/ml) and injectable (10 mg/ml) will be available in the market over the next few weeks. Brivaracetam is approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.

Said, Kirti Ganorkar, CEO – India Business, Sun Pharma, "We are introducing the complete range of Brivaracetam in India at a competitive pricing which will improve patient access. This product reaffirms our commitment towards improving epilepsy care by bringing multiple treatment options to patients and health care professionals in India."

Brivaracetam belongs to the class of anti-epileptic drugs (AEDs) which have a unique or different mechanism of action compared to the existing treatment options. It has fast onset of action and promising efficacy<sup>1</sup>. Long-term studies indicate that the response obtained with the use of Brivaracetam is sustained, with favourable tolerability profile and compliance to the treatment<sup>2</sup>.

While epilepsy is a common neurological disorder, because of the social stigma surrounding epilepsy, cultural practices and poor awareness of new treatment options, management of epilepsy in India continues to be a challenge<sup>3,4</sup>. It is estimated that around 5.7 million to 6.4 million people in India suffer from epilepsy<sup>5,6</sup>.

BRIVIACT® is a trademark of UCB.

## Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website: www.sunpharma.com  
CIN: L24230GJ1993PLC019050



### **Disclaimer:**

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

### **About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050):**

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D. For further information, please visit [www.sunpharma.com](http://www.sunpharma.com) & follow us on Twitter [@SunPharma Live](https://twitter.com/SunPharma_Live)

### **References:**

1. Klein P, Johnson ME, Schiemann J, et al. Time to onset of sustained  $\geq 50\%$  responder status in patients with focal (partial-onset) seizures in three phase III studies of adjunctive brivaracetam treatment. *Epilepsia*. 2017 Feb;58(2):e21-e25
2. Klein P, Diaz A, Gasalla T, Whitesides J. A review of the pharmacology and clinical efficacy of brivaracetam. *Clin Pharmacol*. 2018 Jan 19;10:1-22.
3. Garg D. Specific considerations for epilepsy in India. *Curr Med Issues* 2020;18:105-10.
4. Amudhan S, Gururaj G, Satishchandra P. Epilepsy in India II: Impact, burden, and need for a multisectoral public health response. *Ann Indian Acad Neurol*. 2015 Oct-Dec;18(4):369-81.
5. SRIDHARAN R, MURTHY BN. Prevalence & pattern of epilepsy in India. *Epilepsia* 1999;40:631-6.
6. Banerjee TK, Dutta S, Ray BK, et al. Epidemiology of epilepsy and its burden in Kolkata, India. *Acta Neurol Scand*. 2015 Sep;132(3):203-11.

### **Contact information:**

#### **For Investors:**

Nimish Desai  
Telephone +91 22 4324 4324, Xtn 2778  
Direct +91 22 4324 2778  
Mobile +91-98203 30182  
E mail [nimish.desai@sunpharma.com](mailto:nimish.desai@sunpharma.com)

#### **For Media:**

Gaurav Chugh  
Telephone +91 22 4324 4324, Xtn 5373  
Direct +91 22 4324 5373  
Mobile +91 98104 71414  
E mail [gaurav.chugh@sunpharma.com](mailto:gaurav.chugh@sunpharma.com)